Abstract
A novel 1:1 cocrystal between two cardiovascular drugs, aspirin (ASA) and ligustrazine (tetramethylpyrazine, TMP) has been synthesized and characterized. The structure of this drug-drug cocrystal, ASA-TMP, was determined using single crystal X-ray crystallography. The ASA-TMP cocrystal exhibits a significantly reduced sublimation tendency than TMP. Importantly, cocrystallization simultaneously improves bioavailability of both parent drugs. This suggests the possibility of developing a more effective antithrombosis drug therapy given the synergistic pharmacological effects of the two parent drugs.
Original language | English (US) |
---|---|
Article number | 121541 |
Journal | International journal of pharmaceutics |
Volume | 616 |
DOIs | |
State | Published - Mar 25 2022 |
Bibliographical note
Funding Information:This work was supported by grants from the National Natural Science Foundation of China (Nos. 32002326 and 32172898 ) and Key Research grants of Hebei ( 19227505D ), China. We thank the Minnesota Supercomputing Institute (MSI) at the University of Minnesota for providing the resources that contributed to the research results reported within this paper ( http://www.msi.umn.edu ).
Publisher Copyright:
© 2022 Elsevier B.V.
Keywords
- Antithrombosis
- Aspirin
- Bioavailability
- Cocrystal
- Ligustrazine
PubMed: MeSH publication types
- Journal Article